Education
About Us
Working with TipRanks
Follow Us
Jacobio Pharmaceuticals Group Co., Ltd. (HK:1167)
:1167
Jab-Bx102 (Anti-Cd73 Monoclonal Antibody), Pembrolizumab (Anti-Pd-1 Monoclonal Antibody)
Solid Tumor
Phase I/II
Completed
JAB-BX102 Monotherapy and Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors
Dec 14, 2021
―
Jab-21822 (Kras G12c Inhibitor), Cetuximab (Egfr Inhibitor)
Advanced Solid Tumor, Nsclc, Crc
Phase I/II
Completed
JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation
Jul 26, 2021
―
Jab-8263
Solid Tumors, Adult
Phase I
Completed
A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors
Oct 09, 2020
―
Jab-3068
Non-small Cell Lung Cancer, Esophageal Cancer, Head And Neck Cancer, Other Metastatic Solid Tumors
Phase I
Completed
A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors
Apr 06, 2018
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Jacobio Pharmaceuticals Group Co., Ltd. (1167) have in its pipeline
1167 is currently developing the following drugs: Jab-23E73, Jab-23E73, Jab-30355. These drug candidates are in various stages of clinical development as the company works toward FDA approval.